Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Impact · against what's priced in

Rhythm Pharmaceuticals' positive interim Phase 2 data for setmelanotide in PWS acts as a significant catalyst by validating the drug's efficacy and providing a clear path to Phase 3. The quantification of the US and European addressable market (approx. 8,500-12,750 patients each) provides a concrete basis for future revenue modeling.

RYTM+0.80

No priced-in read yet